Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A 52-week, randomised, double-blind, placebo-controlled, parallel group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype

Placebo-controlled efficacy and safety study of GSK3511294 in participants with severe asthma with an eosinophilic phenotype

There will be 19 in person visits over the course of 15 months where blood, EKGs, and other assessments will occur. You will receive the study drug every 26 weeks.

Timothy Craig
Hunter Smith - at or 717-531-4513

18 year(s) or older
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age or older
Have, or a high likelihood of having eosinophilic asthma
Have at least 2 asthma attacks requiring steroids in the past 12 months
Take daily inhaled corticosteroids

Exclusion Criteria:
Women of childbearing potential must be on contraception
Participants who have received mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero), or benralizumab (Fasenra) within the last 12 months
Participants who have received omalizumab (Xolair) or dupilumab (Dupixent) within last 130 days prior
Current smoker or history of smoking
Lung Disease & Asthma
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,